May 2017
Issuer's Adviser
USD 115 million
Initial Public Offering on NASDAQ
argenx
argenx is a clinical stage biopharmaceutical company creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases